Antag Therapeutics starts Ph 1a trial of AT-7687, GIPR Antagonist
02 Apr 2025 //
GLOBENEWSWIRE
Antag secures $84M series A for GLP-1 add-on
04 Dec 2024 //
FIERCE BIOTECH
Antag Therapeutics Announces €80 Million Series A Financing
04 Dec 2024 //
PR NEWSWIRE
Antag Therapeutics Announces FDA Clearance For IND Application
09 Oct 2024 //
PR NEWSWIRE
Antag Therapeutics appoints Dr. Christine T. Fischette to its Board of Directors
15 Jul 2021 //
PR NEWSWIRE